Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs

Link to article at PubMed

Expert Rev Clin Pharmacol. 2020 Jul 30. doi: 10.1080/17512433.2020.1803740. Online ahead of print.

ABSTRACT

INTRODUCTION: We have summarized and analyzed the clinical trial registration status and the latest research progress of 8 major antiviral drugs during the epidemic of Coronavirus Disease 2019 (COVID-19), which can provide reference methods for clinical formulation of the best antiviral treatment.

AREAS COVERED: We used the generic names of 8 antiviral drugs as keywords to search and analyze the COVID-19-related clinical trials registered in Chinese Clinical Trial Registry and ClinicalTrials.gov. Then we used the keywords to obtain and summarize their clinical research results related to COVID-19 in CNKI, WANFANG, CQVIP and PubMed database.

EXPERT OPINION: The registration system of clinical trials and the level of clinical trial design need to be further improved. At present, no specific drug has been found for the treatment of COVID-19, the efficacy of antiviral drugs mostly comes from small sample studies or retrospective studies, and the level of clinical evidence is low. Besides, multi-drug combination therapy may become a more effective treatment choice, but the drug interactions and adverse drug reactions also need to be closely monitored. In summary, the safety and efficacy of various antiviral drugs need to be confirmed by large samples and high-quality RCT studies.

PMID:32729363 | DOI:10.1080/17512433.2020.1803740

Leave a Reply

Your email address will not be published.